Kitov Receives Nasdaq Notification Regarding Minimum Bid Requirements

Kitov Receives Nasdaq Notification

Regarding Minimum Bid Requirements

TEL AVIV, Israel, July

12, 2019 - Kitov Pharma Ltd. ("Kitov") (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class

therapies to overcome tumor immune evasion and drug resistance, today announced that on July 8, 2019, the Company received a letter

from the Nasdaq Listing Qualification Department indicating that the Company is not in compliance with the continued listing standards

for the Nasdaq Capital Market, due to the Company's current share price.

continued listing on the Nasdaq Capital Market is contingent on regaining compliance during the 180-day period, ending on January

6, 2020. In the event that the Company does not regain compliance during the 180-day period, the Company may be eligible for additional

Pharma (Kitov Pharma Ltd.; NASDAQ/TASE: KTOV) is advancing first-in-class oncology therapies to overcome tumor drug resistance,

increase treatment response rate, and slow tumor progression. Kitov's oncology pipeline includes NT219

a small molecule targeting novel cancer drug resistance pathways and Kitov is under contract to acquire 100% of FameWave Ltd.

which owns CM-24, a humanized monoclonal antibody directed against carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1),

an immune checkpoint protein belonging to the Human CEA (Carcino-Embryonic Antigen) protein family. CM-24 is being developed for

multiple oncological indications according to the expression pattern of its target protein. Following the recent receipt of the

approval of Kitov's shareholders for the acquisition of FameWave, and the finalization of a clinical collaboration agreement

between FameWave and Bristol Myers Squibb (NYSE:BMY) for their planned Phase 1/2 clinical trials to evaluate the combination of

CM-24 with nivolumab (Opdivo ), a PD-1 inhibitor, the acquisition is expected to close during the third quarter

of 2019, subject to fulfillment of certain additional closing conditions. In addition, Kitov's combination drug, Consensi ,

treating osteoarthritis pain and hypertension simultaneously, was approved by the FDA for marketing in the U.S and is partnered

in the U.S, China and South Korea.. For more information on Kitov, the content of which is not part of this press release, please

visit http://www.kitovpharma.com.

Statements and Kitov's Safe Harbor Statement

Certain statements in this press release

that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor

provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited

to, statements that are not statements of historical fact, and may be identified by words such as "believe", "expect",

"intend", "plan", "may", "should", "could", "might", "seek",

"target", "will", "project", "forecast", "continue" or "anticipate"

or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly

to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future

performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events,

and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties

and other factors that may cause our actual results, performance or achievements to be significantly different from any future

results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause

or contribute to such differences include, among others, risks relating to: the lack of assurance that Kitov will be able to regain

compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria; the manner

in which the parties to the transaction for the acquisition of FameWave by Kitov plan to effect the transaction; the expected benefits,

synergies and costs of the transaction; management plans relating to the transaction; the expected timing of the completion of

the transaction; the parties' ability to complete the transaction considering the various closing conditions; the plans,

strategies and objectives of management for future operations; product development for NT219 and CM-24; the potential future financial

impact of the transaction; and any assumptions underlying any of the foregoing; the process by which early stage products such

as CM-24 could potentially lead to an approved product is long and subject to highly significant risks, particularly with respect

to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive process

with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length,

progress and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact of any changes

in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals

necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration

or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and

regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products

once cleared for marketing in a particular market; the introduction of competing products; patents attained by competitors; dependence

on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued

patents with protective claims; the commencement of any patent interference or infringement action; our ability to prevail, obtain

a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or

regulatory actions; the uncertainty surrounding an investigation by the Israel Securities Authority into our historical public

disclosures and the potential impact of such investigation on the trading of our securities or on our clinical, commercial and

other business relationships, or on receiving the regulatory approvals necessary in order to commercialize our products, and other

factors that are discussed in our in our Annual Report on Form 20-F for the year ended December 31, 2018 and in our other filings

with the SEC, including our cautionary discussion of risks and uncertainties under Risk Factors' in our Registration

Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected

results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press

release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking

statement, or other information contained herein, whether as a result of new information, future events or otherwise, except as

required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC,

which are available on the SEC's website, http://www.sec.govFor further information, contact:

Deputy CEO & Chief Financial Officer

+972-3-933-3121 ext. #105

Darren Opland, Ph.D.